Show simple item record

dc.contributor.authorBlanc, J
dc.contributor.authorHubner, Richard A
dc.contributor.authorLi, C
dc.contributor.authorWang-Gillam, A
dc.contributor.authorBodoky, G
dc.contributor.authorDean, A
dc.contributor.authorShan, Y
dc.contributor.authorJameson, G
dc.contributor.authorMacarulla, T
dc.contributor.authorLee, K
dc.contributor.authorCunningham, D
dc.contributor.authorChiu, C
dc.contributor.authorSchwartsmann, G
dc.contributor.authorBraiteh, F
dc.contributor.authorVon Hoff, D
dc.contributor.authorChen, L
dc.contributor.authorMamlouk, K
dc.contributor.authorBhargava, P
dc.contributor.authorde Jong, F
dc.contributor.authorSiveke, J
dc.date.accessioned2017-09-06T12:53:48Z
dc.date.available2017-09-06T12:53:48Z
dc.date.issued2017-06
dc.identifier.citationSubgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy 2017, 28 (suppl_3) Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdx263.017
dc.identifier.urihttp://hdl.handle.net/10541/620533
dc.language.isoenen
dc.relation.urlhttps://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx263.017en
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleSubgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentHospital Haut-Leveque, Bordeaux, Franceen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record